We are not withholding preclinical, clinical and commercial developments. A great deal of news has been released over the last quarter, not least the results of a highly successful Phase 2 clinical trial of bisantrene.
Continuing to rehash over the decisions made by past management is not helpful. We detailed what we are going to do in November and we are keeping everyone updated as to our progress. Everything is on track and progressing well with RC220 expected to be delivered this quarter and the non-clinical safety testing completed by the middle of the year. This will allow us to get back into the clinic in the second half of 2024 with RC220. All of this work is fully funded.
RAC - Charts & Price Action, page-18979
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.89 |
Change
0.120(6.80%) |
Mkt cap ! $321.0M | |||
| Open | High | Low | Value | Volume |
| $1.78 | $1.93 | $1.78 | $563.4K | 302.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 108 | $1.88 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.90 | 4926 | 1 |
View Market Depth
| Last trade - 16.10pm 11/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |